Purpose: To evaluate the association between the biological disease-modifying anti-rheumatic drugs (bio-DMARDs) and the incidence of diabetes.

Methods: Studies recording the incidence of new-onset diabetes in subjects treated with bio-DMARDs were included.

Results: In total, 23 relevant studies were included. The pooled analysis suggested that bio-DMARDs treatment did not reduce the incidence of diabetes (RR= 0.87, 95% CI, 0.69 to 1.08, P = 0. 21) compared with non-bioDMARDs. However, subgroup analyses revealed incidence of new-onset diabetes was significantly reduced in patients with abatacept treatment (RR = 0.61, 95% CI, 0.38 to 0.99, P = 0.04).

Conclusions: The utilization of bio-DMARDs in general was not associated with the incidence of diabetes while the abatacept treatment may reduce the risk of diabetes.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

C. Lin: None. H. Ji: None. X. Cai: None. W. Yang: None. L. Ji: None.

Funding

National Natural Science Foundation of China (81970698); National Key Research and Development Program of China (2016YFC1304901)

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.